Abstrakt
Acute ischaemic stroke (AIS) is a devastating disease associated with high morbidity and mortality, ranking 2nd single most common cause of death in Europe1 and 4th cause of death in the USA.2 Based on the 2014 American Heart Association statistic, 795 000 US Americans experienced a stroke annually, 87% related to ischaemic, and 10% to haemorrhagic events with 3% related to sub-arachnoidal bleeding.2 According to the current guidelines, systemic fibrinolysis is reserved for patients treated within 3 h after the onset of ischaemic symptoms (recommendation I/A) or within 3-4.5 h after the onset of ischaemic symptoms (recommendation I/B). Here, we briefly compare the interventional approach to AIS and STEMI and suggest a novel fast-track approach to AIS management